Holen Sie sich die Stockscreener-App
2.01
1.95%
-0.04
Bioline Rx Ltd Adr Aktie (BLRX) Neueste Nachrichten
BioLineRx and Hemispherian to present GLIX1 data at SNO meeting - Investing.com
One covers lab models; another outlines a trial testing an experimental brain tumor treatment. - Stock Titan
BioLineRx Ltd. SEC Filing (Oct 5, 2026) - Stock Titan
Biolinerx Stock Price Forecast. Should You Buy BLRX? - StockInvest.us
BioLineRx Ltd (NASDAQ: BLRX) Share Price, BLRX Stock News, BLRX Share Price & Updates - kalkine.ca
Current ratio of BioLineRX Ltd. Sponsored ADR – HAN:YP2 - TradingView
BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 - lelezard.com
YP2 Forecast — Price Target — Prediction for 2027 - TradingView
BioLineRx Files Form F-1 to Register Resale of 2,023,382 ADSs Linked to August 2026 Warrants - Kalkine Media
$5.6 million could go to BioLineRx (Nasdaq: BLRX) if all warrants are exercised for cash. - Stock Titan
Every proposal passed at BioLineRx (BLRX)’s September 23 annual meeting. - Stock Titan
BioLineRx Ltd (NASDAQ: BLRX) Share Price, BLRX Stock News, BLRX Share Price & Updates - Kalkine
BioLineRx Ltd.American Depositary Shares (Nasdaq:BLRX) Detailed Stock Data - The Chronicle-Journal
Diluted net income available to common stockholders of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - TradingView
Total revenue of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - tradingview.com
BioLineRx, Hemispherian to present GLIX1 data at EANO meeting - Investing.com
BioLineRx and Hemispherian to Showcase GLIX1 Glioblastoma Data and Trial Design at EANO 2026 - TipRanks
A drug candidate cut tumor growth and extended survival in mice. Human testing is enrolling. - Stock Titan
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) – Company AnnouncementFT.com - Financial Times
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) - Yahoo Finance
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) - PR Newswire
Long term debt to total assets ratio of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - tradingview.com
Return on equity % of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - TradingView
BioLineRx (BLRX) sells warrants to fund R&D push - Stock Titan
BioLineRX Ltd. Sponsored ADR Statistics – HAM:YP2 - TradingView
YP2 Stock Price and Chart — HAM:YP2 - TradingView
YP2 Forecast — Price Target — Prediction for 2027 - TradingView
YP2 Stock Price and Chart — HAM:YP2 - TradingView
YP2 Stock Price and Chart — HAM:YP2 - TradingView
YP2 Stock Price and Chart — HAM:YP2 - TradingView
BLRX: New GLIX1 Data Touts Synergies - Yahoo Finance
BioLineRx Earnings Call Highlights GLIX1 Momentum - TipRanks
BioLineRx (NASDAQ: BLRX) Announces $3.3M Net Raise via 480,696 ADSs at $2.78 Each - Kalkine Media
BioLineRx Raises $3.75 Million in August Registered Direct Offering and Warrant Deal - TipRanks
BioLineRx Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: BioLineRx Q2 2026 revenue flat as GLIX1 advances - Investing.com
BioLineRx Advances GLIX1 Oncology Program and Posts Q2 2026 Results - TipRanks
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
BioLineRx (BLRX) lines up new ADS and warrant funding round - Stock Titan
BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1 Pipeline and ... - Yahoo Finance
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
BioLine RX Ltd (BLRX) JUN/2026 Earning Prediction - Intellectia AI
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - Sahm
BioLineRx stock falls on $3.75M share offering plan - Investing.com India
BioLineRx stock falls on $3.75M share offering plan - Investing.com
BioLineRx Raises $3.75 Million in Registered Direct Offering, Retires ATM Facility - TipRanks
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - Barchart.com
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - PR Newswire
BioLineRx (BLRX) lines up $3.75M raise, ends ATM facility - Stock Titan
BioLineRx raises $3.75 million in registered direct offering - Investing.com
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):